Notable Runner: Zeltiq Aesthetics Inc Just Reaches Record High?

Notable Runner: Zeltiq Aesthetics Inc Just Reaches Record High?

The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) reached all time high today, Nov, 29 and still has $45.01 target or 5.00% above today’s $42.87 share price. This indicates more upside for the $1.70 billion company. This technical setup was reported by Barchart.com. If the $45.01 PT is reached, the company will be worth $85.00M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 403,637 shares traded hands. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has risen 35.73% since April 26, 2016 and is uptrending. It has outperformed by 30.47% the S&P500.

Analysts await Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) to report earnings on March, 6. They expect $0.16 EPS, up 220.00% or $0.11 from last year’s $0.05 per share. ZLTQ’s profit will be $6.34 million for 66.98 P/E if the $0.16 EPS becomes a reality. After $0.12 actual EPS reported by Zeltiq Aesthetics Inc for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) Ratings Coverage

Out of 7 analysts covering Zeltiq Aesthetics (NASDAQ:ZLTQ), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Zeltiq Aesthetics has been the topic of 13 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, November 10 by Canaccord Genuity. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, September 1. The firm has “Outperform” rating by Leerink Swann given on Wednesday, October 28. The stock has “Outperform” rating given by William Blair on Wednesday, August 26. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, September 21. The firm has “Neutral” rating given on Tuesday, August 9 by JP Morgan. The stock has “Buy” rating given by Maxim Group on Wednesday, October 28. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) earned “Buy” rating by Griffin Securities on Friday, January 22. The stock has “Buy” rating given by Brean Capital on Wednesday, April 13.

According to Zacks Investment Research, “Zeltiq Aesthetics Inc. is a medical technology company engaged in designing, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally. Zeltiq Aesthetics Inc. is based in Pleasanton, California.”

Insitutional Activity: The institutional sentiment increased to 1.47 in Q2 2016. Its up 0.11, from 1.36 in 2016Q1. The ratio improved, as 28 funds sold all Zeltiq Aesthetics Inc shares owned while 42 reduced positions. 25 funds bought stakes while 70 increased positions. They now own 43.91 million shares or 2.50% more from 42.84 million shares in 2016Q1.
Millennium Ltd Liability Corporation reported 958,442 shares or 0.06% of all its holdings. Yorktown Mngmt & Research Inc holds 0.05% or 8,500 shares in its portfolio. The California-based Osterweis Mgmt Incorporated has invested 0.16% in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Comerica Commercial Bank holds 32,382 shares or 0.01% of its portfolio. Advsr Asset Mngmt has 47,494 shares for 0.02% of their US portfolio. Finemark Retail Bank Tru has 0% invested in the company for 105 shares. The Georgia-based Advisory Svcs Networks has invested 0.01% in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Mercer Cap Advisers owns 1,100 shares or 0.02% of their US portfolio. Huntington Bancshares accumulated 2,069 shares or 0% of the stock. Blair William And Il holds 0.03% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 116,957 shares. Drill Craig A accumulated 12.4% or 230,200 shares. Riverbridge Ltd Liability Company last reported 0.66% of its portfolio in the stock. Samlyn Ltd Company holds 0.77% or 1.18 million shares in its portfolio. Goldman Sachs Grp holds 54,144 shares or 0% of its portfolio. Blackrock Fund Advsrs holds 0.01% or 2.30M shares in its portfolio.

Insider Transactions: Since July 11, 2016, the stock had 0 insider purchases, and 19 sales for $27.17 million net activity. $264,058 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares were sold by Sullivan Keith J. OBOYLE KEVIN C sold $300,612 worth of stock or 7,500 shares. 3,125 shares were sold by Lamm Carl, worth $125,000 on Thursday, September 15. Another trade for 10,000 shares valued at $405,465 was made by Foley Mark J on Thursday, October 13. SCHIFF ANDREW N sold $18.20 million worth of stock. Hauser Bradley sold $90,075 worth of stock or 3,000 shares. $781,548 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) was sold by Garcia Sergio.

More recent Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) news were published by: Fool.com which released: “Why Zeltiq Aesthetics Inc. Is Soaring Today” on November 10, 2016. Also Nasdaq.com published the news titled: “Earnings Reaction History: ZELTIQ Aesthetics, Inc., 40.0% Follow-Through …” on October 27, 2016. Fool.com‘s news article titled: “Zeltiq Aesthetics Earnings: Keeping Up Appearances” with publication date: August 08, 2016 was also an interesting one.

ZLTQ Company Profile

ZELTIQ Aesthetics, Inc., incorporated on March 22, 2005, is a medical technology company. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Firm sell its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment